Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | DTYMK | P23919 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | POLR1A | O95602 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4380367 | 0.84 | GAA (0.44) | DTYMKKDM4EBRD4NAMPTPOLR1A | |
| SCHEMBL4392206 | 0.83 | PARP1 (0.44) | PARP1KDM4E | |
| SCHEMBL4385936 | 0.81 | PRKCG (0.47) | DTYMKKDM4EUSP30GPR119 | |
| SCHEMBL1589994 | 0.78 | PARP1 (0.47) | PARP1HDAC1HDAC2DTYMKKDM4E | |
| SCHEMBL1589991 | 0.72 | BACE1 (0.47) | PARP1DTYMKKDM4EGPR119 | |
| SCHEMBL25939069 | 0.70 | PRKCG (0.51) | KDM4EGPR119CHRM2CHRM4CHRM1 | |
| SCHEMBL12724959 | 0.69 | PARP1 (0.45) | PARP1KDM4EBRD4NAMPT | |
| SCHEMBL28700999 | 0.69 | NAMPT (0.43) | KDM4EBRD4USP30NAMPTRORC | |
| SCHEMBL30861478 | 0.69 | NAMPT (0.43) | KDM4EBRD4USP30NAMPTRORC | |
| SCHEMBL20485580 | 0.68 | CHRM2 (0.47) | DTYMKKDM4EUSP30NAMPTRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298825-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | RENOVIS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-20090298825-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | RENOVIS, INC. | 2009-12-03 | — | — | US | disclosed |
| EP-1996585-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | Renovis, Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007109154-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298825-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX1 | PARP1 1868/4885HDAC1 2168/4885HDAC2 1574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.